CAS1 domain sialic acid O acetyltransferase 1Genealiases: C7orf12 · Cas1 · Cas1p · NBLA04196 · SOAT
Q-omics provides the consensus-scored CASD1 profile across patient tissues and cancer cell-line models. CASD1 expression is associated with patient survival in 27 of 34 cancer types, with the highest sampling consensus in LUAD. Among the 18 cancer types available for tumor–normal comparison, CASD1 is differentially expressed in 14, with the highest sampling consensus in COAD. Additionally, CASD1 RNA expression shows 21,467 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight LUAD, COAD, and UVM as cancer lineages where CASD1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CASD1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CASD1 survival associations across molecular data types. CASD1 RNA expression shows survival associations in the most cancer types (27), followed by mutation status (5) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CASD1 RNA expression–survival associations across cancer types. High CASD1 expression shows unfavorable associations in CESC, KICH and STAD, but favorable associations in LUAD, BRCA and UCS. The LUAD Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .001). Together, the overview and detailed table identify LUAD as the clearest survival context for CASD1 RNA expression.
This table summarizes CASD1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 3. The strongest signals are observed in COAD for RNA and COAD for protein.
This table ranks reproducible tumor–normal expression differences for CASD1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CASD1 shows lower tumor expression in COAD, LUSC, READ and UCEC and higher tumor expression in LIHC and CHOL. The COAD box plot shows higher CASD1 RNA expression in normal versus tumor tissue (log2 FC = −1.234, t-test p < 0.001).
This table shows molecular features associated with CASD1 in patient tissues and cancer cell lines. In patient samples, CASD1 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, CASD1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BONE, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Lymphoma and BLOOD_Leukemia.
